Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial  fibrillation complicated with cardiac insufficiency

doi:10.3969/j.issn.1004-583X.2020.05.005

Abstract

Abstract: Objective To analyze the clinical efficacy and safety of rivaroxabanin elderly patients with nonvalvular atrial fibrillation (NVAF) complicated with cardiac insufficiency. Methods A total of 182 elderly NVAF patients complicated with cardiac insufficiency who were admitted to the hospital from January 2016 to January 2020 were enrolled. The patients were randomly divided into two groups, 91 cases were selected for rivaroxaban anticoagulation as observation group, and other 91 cases were treated with warfarin anticoagulation as control group. The adverse events including thrombotic events, hemorrhage, and coagulation, as well as the coagulation function and cardiac function were recorded during the followup in two groups. Results The total bleeding events in observation group were significantly lower than those in control group. NTproBNP of observation group significantly decreased compared with that of control group after treatment. COX risk model found that the age and warfarin were risk factors for adverse events. Conclusion Rivaroxaban is not inferior to warfarin in treating the elderly NVAF patients complicated with cardiac insufficiency, but its safety is significantly higher than that of warfarin.

Key words: atrial fibrillation, nonvalvular; , rivaroxaban, cardiac insufficiency; , the elderly; , efficacy, safety

Ma Jincai, Ma Rongzhi, Ma Zhenzhen. Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2020.05.005.

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2020.05.005

https://lchc.magtechjournal.com/EN/Y2020/V35/I5/413

[1]	Tang Xu, Zuo Zhuang, Yang Kai, Zhang Zhiyuan, Wang Qi, Dong Xinchun, Gou Yunjiu. The efficacy and safety of anti-angiogenic drugs combined with chemotherapy in treating malignant pleural mesothelioma: An updated systematic review and meta-analysis [J]. Clinical Focus, 2025, 40(4): 304-312.
[2]	Huang Xingzhou, Zheng Weihua, Zhang Shutong, Chen Yanhao. Clinical efficacy and safety of drug-eluting beads for bronchial artery chemoembolization versus conventional bronchial artery chemoembolization alone for advanced non-small cell lung cancer [J]. Clinical Focus, 2025, 40(3): 243-250.
[3]	Yue Jianghong, Wang Heng, Cai Gang, Zhang Xuanming, Peng Xi. Efficacy and safety of sotagliflozin in the treatment of type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2024, 39(7): 581-592.
[4]	Yu Jingyi, Si Yuanguo, Lan Cuixia, Xing Jiaxuan. Safety and efficacy of rivaroxaban in the treatment of discharged COVID-19 patients: A meta-analysis [J]. Clinical Focus, 2024, 39(6): 485-493.
[5]	Liu Junyu, Zhang Tiancai, Zhang Baie, Li Yizhou, Li Yafei, Liu Hongbin, Duan Liping, Zhang Quanying, Wang Yijun, Meng Fanhua, Sun Min. Bioequivalence of aspirin enteric-coated tablet in healthy volunteers [J]. Clinical Focus, 2024, 39(5): 433-439.
[6]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[7]	Zhu Chunyu, Lin Chunyi, Weng Lan, Yang Xunjie, Dong Dihui. Efficacy and safety of high-power short-duration on the modified box isolation for persistent atrial fibrillation [J]. Clinical Focus, 2024, 39(10): 915-920.
[8]	Qin Qiaoling, Mo Ranghui, Chen Xinyi. Efficacy and safety of the direct-acting anti-HCV therapy based on efavirenz-containing regimen on HIV/HCV co-infected patients [J]. Clinical Focus, 2024, 39(10): 921-924.
[9]	Li Hai, Liu Wenhu, Peng Shaopeng, Wang Fei. Meta-analysis of the efficacy of controlled stepwise decompression versus rapid standard large bone-flap decompression on the treatment of severe craniocerebral injury [J]. Clinical Focus, 2023, 38(9): 788-795.
[10]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[11]	Zhang Fang, Zhang Yichao, Jia Xinwei, Li Jianlong, Chen Chunhong. Analysis of one-year follow-up results of ≥75-year-old atrial fibrillation inpatients with high CHA2DS2-VASc score [J]. Clinical Focus, 2023, 38(2): 117-120.
[12]	Ma Jinghong, Yang Qian, Jia Yongjian, Dang Yi. Risks of cardiac tamponade resulting from uninterrupted novel oral anticoagulants and uninterrupted warfarin during perioperative period of catheter ablation of atrial fibrillation: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 773-778.
[13]	Wang Tengyan, He Yajun, Shu Jianchang. Rebamipide in the treatment of nonsteroidal anti-inflammatory drug-associated intestinal disease: A meta-analysis [J]. Clinical Focus, 2022, 37(8): 685-690.
[14]	Zhang Haifu, Ye Xiangqing, Chen Zhexu, Chen Shijian, Yang Dong, Zhang Xingwei. Effects of moderate exercise on the prognosis of patients with atrial fibrillation:A systematic review and Meta-analysis [J]. Clinical Focus, 2022, 37(6): 485-489.
[15]	Zhang Jingshui, Xu Yanan, Wang Jun, Yang Yi, Jiang Haibing, Tang Long, Wang Xianping, Shao Mingliang. Clinical characteristics and long-term prognosis of initial patients with new onset different type of heart failure combined atrial fibrillation [J]. Clinical Focus, 2022, 37(6): 504-509.

Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments